Pharmacokinetics and Pharmacodynamics of Ibrexafungerp.

Abstract

On 2 June, 2021, the US Food and Drug Administration approved ibrexafungerp (formerly MK-3118 and SCY-078) for the treatment of vulvovaginal candidiasis, also known as vaginal yeast infection. Ibrexafungerp is the first drug approved in a novel antifungal class in more than two decades, and the Food and Drug Administration's decision was based on positive results from two pivotal phase III studies in which oral ibrexafungerp proved both safe and effective in patients with vulvovaginal candidiasis. The decision was also based on substantial preclinical and clinical work in both the pharmacokinetics and pharmacodynamics of ibrexafungerp. This paper reviews that research and looks ahead to explore how this novel antifungal agent may be used in the future to address the expanding problem of drug-resistant mycotic infections.

• Authors: Matthew William McCarthy
• Journal: Drugs in R&D (Drugs R D) Vol. 22 Issue 1 Pg. 9-13 (Mar 2022) ISSN: 1179-6901 [Electronic] New Zealand
• PMID: 34961907 (Publication Type: Journal Article, Review)
• Copyright: © 2021. The Author(s).

Chemical References

• Antifungal Agents
• Glycosides
• Triterpenes
• ibrexafungerp

Topics

• Antifungal Agents (pharmacology, therapeutic use)
• Candidiasis, Vulvovaginal (drug therapy)
• Female
• Glycosides (pharmacology, therapeutic use)
• Humans
• Triterpenes (pharmacology, therapeutic use)
• United States